Biggest News Aggregation in the World
๐Ÿ“ฐ Colitis Center News

Page 2 - Colitis Center News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Colitis Center. Real-time updates on events, politics, business and more.

First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study...
Spring House British Columbia United States Craig Stoltz Jessicar Allegretti National Institutes Of Health

Johnson & Johnson : First Phase 3 TREMFYA® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis

That cause chronic inflammation of the gastrointestinal tract.6 Prolonged inflammation results in damage to the GI tract.6 The exact cause of IBD is unknown but may be the result of the immune... | May 9, 2023
United States Spring House Jessicar Allegretti Craig Stoltz National Institutes Of Health Colitis Center

Dr Jessica Allegretti: Major Advancements Being Explored for Prevention, Treatment of CDI

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, reviews emerging therapeutics being investigated for the prevention and treatment of Clostridioides difficile infection (CDI).
Jessica Allegretti Colitis Center Seres Therapeutics Vedanta Biosciences Finch Therapeutics Infectious Disease
Source: ajmc.com

Dr Jessica Allegretti Addresses Rebyota Utilization, Access Considerations for Recurrent CDI

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, speaks on current indications for Rebyota (fecal microbiota, live-jslm) in the treatment of recurrent Clostridioides difficile infection (CDI), as well as coverage and access-related implications for the drug.
Jessica Allegretti Colitis Center Infectious Disease Clostridioides Difficile Infection Recurrent Clostridioides Difficile Infection Fecal Microbiota Transplantation
Source: ajmc.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Dr Jessica Allegretti on Prevention and Treatment Strategies for Primary, Recurrent CDI

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, discusses the standard of care for the prevention and treatment of primary and recurrent Clostridioides difficile infection (CDI).
Jessica Allegretti Infectious Disease Society American College Of Gastroenterology Colitis Center American College Infectious Disease
Source: ajmc.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science